Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04721808 · ClinicalTrials.gov registry record

A Study To Investigate And Describe The Treatment Patterns And Effect Of Tofacitinib Indicators For Patients With Rheumatoid Arthritis

A clinical trial, sponsored by Pfizer.

Completed
Registry status
1,712
Enrollment target

NCT04721808: Completed study, sponsored by Pfizer.

NCT04721808 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 1,712 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04721808 has completed, sponsored by Pfizer.

COMPLETED
Registry status
1,712 participants
Enrollment target

Study Summary

This study is to investigate and describe the treatment patterns and effect of tofacitinib indicators for patients with Rheumatoid Arthritis (RA) assessing real world patient data entered in the Corrona RA Registry on or after November 2012

Primary Outcome

CDAI is a composite index for assessing disease activity based on the numerical summation of four components: tender joint count and swollen joint count (both out of 28 evaluated joints), patient global assessment of disease activity and physician global assessment of disease activity both measured on a visual analog scale (VAS) from 0 to 100 millimeter (mm); higher scores=higher disease activity. CDAI total score ranged from 0 to 76 where lower scores=lower disease activity. A score of \<=10 in

Trial Details

FieldValue
Enrollment Target 1,712 participants
Start Date 2021-01-22
Est. Completion 2021-11-24
Pfizer

1,845 total trials

What the finished NCT04721808 record still lists

NCT04721808 is an observational study that tracks outcomes without assigning an intervention. Its 1,712 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 0 interventions.

NCT04721808 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04721808 about?

NCT04721808 is a clinical study titled "A Study To Investigate And Describe The Treatment Patterns And Effect Of Tofacitinib Indicators For Patients With Rheumatoid Arthritis". This study is to investigate and describe the treatment patterns and effect of tofacitinib indicators for patients with Rheumatoid Arthritis (RA) assessing real world patient data entered in the Corrona RA Registry on or after November 2012

What is the current status of trial NCT04721808?

This trial is currently completed. The enrollment target is 1,712 participants. The study started on 2021-01-22. Estimated completion is 2021-11-24.

Who is sponsoring clinical trial NCT04721808?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05303636 · 1,710 participants · Phase 4

    LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

  • NCT04291612 · 1,715 participants

    Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

  • NCT07304531 · 1,705 participants

    First To Know Pregnancy Test - Clinical Evaluation Protocol

  • NCT04321200 · 1,700 participants

    PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04721808, the US trial registry maintained by the National Library of Medicine. NCT04721808 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.